1041 Implementation of a Chronic Hepatitis Panel to Improve Viral Hepatitis Screening in Chronic Liver Disease

2019 ◽  
Vol 114 (1) ◽  
pp. S593-S594
Author(s):  
Chandraprakash Umapathy ◽  
Jonathan Pham ◽  
Linda Stokes ◽  
Marina Roytman
Blood ◽  
2010 ◽  
Vol 116 (16) ◽  
pp. 2875-2883 ◽  
Author(s):  
Vito Di Marco ◽  
Marcello Capra ◽  
Emanuele Angelucci ◽  
Caterina Borgna-Pignatti ◽  
Paul Telfer ◽  
...  

AbstractChelation therapy with new drugs prevents cardiac damage and improves the survival of thalassemia patients. Liver diseases have emerged as a critical clinical issue. Chronic liver diseases play an important role in the prognosis of thalassemia patients because of the high frequency of viral infections and important role of the liver in regulating iron metabolism. Accurate assessment of liver iron overload is required to tailor iron chelation therapy. The diagnosis of hepatitis B virus– or hepatitis C virus–related chronic hepatitis is required to detect patients who have a high risk of developing liver complications and who may benefit by antiviral therapy. Moreover, clinical management of chronic liver disease in thalassemia patients is a team management issue requiring a multidisciplinary approach. The purposes of this paper are to summarize the knowledge on the epidemiology and the risks of transmission of viral infections, to analyze invasive and noninvasive methods for the diagnosis of chronic liver disease, to report the knowledge on clinical course of chronic viral hepatitis, and to suggest the management of antiviral therapy in thalassemia patients with chronic hepatitis B or C virus or cirrhosis.


Hepatology ◽  
1999 ◽  
Vol 29 (3) ◽  
pp. 883-888 ◽  
Author(s):  
Thomas R. Frieden ◽  
Lisa Ozick ◽  
Colin McCord ◽  
Omana V. Nainan ◽  
Sara Workman ◽  
...  

Hepatology ◽  
1997 ◽  
Vol 25 (5) ◽  
pp. 1271-1275 ◽  
Author(s):  
M W Fried ◽  
Y E Khudyakov ◽  
G A Smallwood ◽  
M Cong ◽  
B Nichols ◽  
...  

2001 ◽  
Vol 195 (4) ◽  
pp. 473-481 ◽  
Author(s):  
Mimoun Nejjari ◽  
Anne Couvelard ◽  
Jean-Fran�ois Mosnier ◽  
Alain Moreau ◽  
G�rard Feldmann ◽  
...  

2020 ◽  
Vol 26 (2) ◽  
pp. 209-215 ◽  
Author(s):  
Seung Ha Park ◽  
Lindsay D. Plank ◽  
Ki Tae Suk ◽  
Yong Eun Park ◽  
Jin Lee ◽  
...  

Data on the trends in the prevalence of chronic liver disease (CLD) in Korea are scarce. This study aimed to evaluate whether the CLD prevalence changed between 1998–2001 and 2016–2017. Data were extracted from the Korea National Health and Nutrition Examination Survey (1998–2001 to 2016–2017; n=25,893). Non-alcoholic fatty liver disease (NAFLD) was defined as a hepatic steatosis index >36 in the absence of any other evidence of CLD. The definition of alcoholrelated liver disease (ALD) was excessive alcohol consumption (≥210 g/week for men and ≥140 g/week for women) and an ALD/NAFLD index >0. The prevalence of NAFLD increased from 18.6% (95% confidence interval [CI], 17.8–19.5%) in 1998–2001 to 21.5% (95% CI, 20.6–22.6%) in 2016–2017. During the same time period, increases were observed in the prevalence of obesity (27.0 vs. 35.1%), central obesity (29.4 vs. 36.0%), diabetes (7.5 vs. 10.6%), and excessive drinking (7.3 vs. 10.5%). ALD prevalence also increased from 3.8% (95% CI, 3.4–4.2%) to 7.0% (95% CI, 6.4–7.6%). In contrast, chronic hepatitis B decreased from 5.1% (95% CI, 4.6–5.5%) to 3.4% (95% CI, 3.0–3.8%). The prevalence of chronic hepatitis C was approximately 0.3% in 2016–2017. The prevalence of NAFLD and ALD increase among Korean adults. Our results suggest potential targets for interventions to reduce the future burden of CLD.


2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Shih-Yung Su ◽  
Long-Teng Lee ◽  
Wen-Chung Lee

Abstract Background Globally, the morbidity and mortality rates for chronic liver disease and cirrhosis are increasing. The National Viral Hepatitis Therapy Program in Taiwan was implemented in 2003, but evidence regarding the program’s effect on the trends of mortality for chronic liver disease and cirrhosis is limited. Methods We analyzed mortality rates for chronic liver disease and cirrhosis in Taiwan for the period from 1981 to 2015. An autoregressive age–period–cohort model was used to estimate age, period, and cohort effects. Results Age-adjusted mortality rates for chronic liver disease and cirrhosis all displayed a flat but variable trend from 1981 to 2004 and a decreasing trend thereafter for both sexes. The age–period–cohort model revealed differential age gradients between the two sexes; mortality rates in the oldest age group (90–94 years) were 12 and 66 times higher than those in the youngest age group (30–34 years) for men and women, respectively. The period effects indicated that mortality rates declined after 2004 in both sexes. Mortality rates decreased in men but increased in women in the 1891–1940 birth cohorts and increased in both sexes in the birth cohorts from 1950 onward. Conclusions The National Viral Hepatitis Therapy Program in Taiwan may have contributed to the decrease in mortality rates for chronic liver disease and cirrhosis in adulthood.


2013 ◽  
Vol 50 (2) ◽  
pp. 97-100 ◽  
Author(s):  
Fernanda Maria Farage OSÓRIO ◽  
Gabriel Martin LAUAR ◽  
Agnaldo Soares LIMA ◽  
Paula Vieira Teixeira VIDIGAL ◽  
Teresa Cristina Abreu FERRARI ◽  
...  

Context Studies on epidemiology of hepatocellular carcinoma and modalities of therapy used to treat this condition are scarce in Brazil. Our aim was to characterize hepatocellular carcinoma according to etiology of the underlying chronic liver disease, and treatment modalities, in a referral center in Brazil. Methods All cases of hepatocellular carcinoma registered in the Department of Pathology during a 12-year period (1998-2010) were included. Demographic data, etiology of the underlying liver disease and treatment performed were collected. Results This case series included 215 patients, mean age 57.3 (± 14.1) years, 164 (76.2 %) male. Virus C and virus B infection were detected in 88 (43%) and 47 (23%) patients, respectively. Ethanol abuse alone or combined with other etiologies was identified in 64 (32%) individuals. Schistosomiasis was found in 18 (9%) patients. Liver transplantation was the treatment of choice in 112 (51%) patients. This procedure was more frequently performed in hepatitis C virus-related hepatocellular carcinoma (70%) than B virus-related hepatocellular carcinoma (17%). Tumor resection was performed in 40 (18%) individuals, ethanol injection or thermo ablation in 18 (14%), and chemoembolization in 14 (7%). In 40 (19.4%) patients no treatment was performed and this percentage remained constant over the years. Conclusions Chronic hepatitis C, followed by ethanol abuse and chronic hepatitis B were the leading causes of underlying chronic liver disease associated with hepatocellular carcinoma. The results show a trend of increasing incidence of hepatocellular carcinoma; however, the proportion of untreated patients remained constant over the analyzed period.


Sign in / Sign up

Export Citation Format

Share Document